Hotline 24/7: 0909384389

Share links:

TIDES-ACS confirms performance of Hexacath’s titanium-nitride-oxide coated stent

Ngày 16/09/2020 09:02 | Lượt xem: 1050

Results of the TIDES-ACS randomised controlled trial, confirming the superior safety and sustained non-inferior efficacy of the Bio-Active Stent technology (Hexacath) at 18 months follow-up versus a drug-eluting stent, have been published.

Conducted in 12 international sites, the study randomised 1,491 acute coronary syndrome (ACS) patients (2:1) to receive either TiNO bio-active coated stent (OPTIMAX, Hexacath) versus Everolimus pharmacologically active stent (SYNERGY, Boston Scientific) in ACS patients.

The co-primary safety endpoint (a composite of cardiac death, re-infarction and major bleeding) occurred in 3.7% of patients receiving TiNO-coated stents versus 7.8% of those receiving EES (HR 0.64 [95% CI 0.51 – 0.80] p=0.001) demonstrating the superiority of the TiNO bio-active stent.

Individual cardiac safety events components at 18 months were cardiac death (0.6% versus 2.6%; HR 0.49 [95% CI 0.36 – 0.67], p=0.002), non-fatal MI (2.2% versus 5.0%; HR 0.62 [95% CI 0.47 – 0.82], p=0.007) and major bleeding (1.4% versus 2.4%; HR 0.73 [95% CI 0.48 – 1.11], p=0.209). Definite or probable stent thrombosis occurred in 1.1% with OPTIMAXTM versus 3.0% with SYNERGYTM (HR 0.58 [95% CI 0.41 – 0.81], p=0.012). Interestingly, ischaemia-driven TLR difference was not significant between both groups (5.8% versus 4.4%; HR 1.22 [95% CI 0.85 – 1.75], p=0.274).

“At 18 months post percutaneous coronary intervention (PCI), the TIDES-ACS results reveal that the OPTIMAX nitride-oxide coated stent is superior in patients with acute coronary syndrome compared to one of the top drug-eluting stents (SYNERGY) used in current interventional cardiology,” said Pasi Karjalainen, Helsinki University Hospital, Helsinki, Finland.

The co-primary non-inferiority endpoint was the rate of major adverse cardiac events (MACE): a composite of cardiac death, non-fatal myocardial infarction (MI) and ischemia-driven target lesion revascularisation (TLR) at 12 months. The co-primary endpoint was met at 12 months, as MACEoccurred in 6.3% with OPTIMAXTM versus 7.0% with SYNERGYTM (HR 0.93 [95% CI 0.71 – 1.22] p for non-inferiority <0.001, p for superiority=0.66). The 18 months published results demonstrated the sustained efficacy in terms of efficacy of the TiNO bio-active stent technology as the rate of MACE was 7.2% with OPTIMAXTM versus 8.8% with SYNERGYTM (HR 0.87 [95% CI 0.68 – 1.11], p=0.304).

“The TIDES-ACS results show that the OPTIMAX nitride-oxide coated stent is non-inferior (MACE) in patients with acute coronary syndrome compared to one of the best-in-class drug-eluting stents (SYNERGY) used in current interventional cardiology,” said Pim Tonino, Heart center Catharina Hospital, Eindhoven, the Netherlands.

In conclusion, in patients with ACS, cobalt-chromium based TiNO coated stents were non-inferior to platinum-chromium–based biodegradable polymer EES for major cardiac events at 12 and 18 months and were superior for the co-primary safety endpoint a composite of cardiac death, MI, and major bleeding at 18 months follow up without compromising the TLR rate (p=0.274).

Source CardiovascularNews

Duc Tin Clinic

Tin tức liên quan

Enrolment reaches midway point in trial of Early Bird bleed monitoring system

Eight-fold increased risk of heart attack seen in patients with subclinical obstructive coronary atherosclerosis

ACC 2023: REVIVED-BCIS-2 results challenge “long-held beliefs” on myocardial viability testing prior to PCI

Blood pressure successfully cut in RADIANCE II ultrasound renal denervation trial

New data examine mortality rates and cardiac damage in early-stage aortic stenosis patients

SUPPORT CONSULTANT

CUSTOMER REVIEWS

• I am Nguyen Thanh Sang, born in 1990. Since the examination and treatment at the clinic Duc Tin, I am very grateful to the Doctor for explaining and sharing about my illness. During the treatment time in the clinic I was very caring staff of the clinic. Now my illness has improved in a good way. Expect more and more clinic to be able to save many patients.

  I sincerely thank you !. Tel: 0938303275

• Huynh Thi Muoi, born in 1940, was examined and treated at Duc Tin Clinic. I am very pleased about how to serve and care patients of the clinic. The doctor is committed to explaining and sharing with the patient.

  Huynh Thi Muoi sincerely thank you! Phone number: 0972868746

• As I said Duc Tin surgical clinin is where my family trust, hope to visit. Physicians caring, thoughtful, gentle to the patient. Nurses and staff clinic polite, cheerful and thoughtful. This clinic clean, sterile, so I would love to. Tel: +84949914060.

• The doctor is very caring, attentive and very gentle nurse, courteous, affable with me. The clinic is clean, comfortable, polite. I enjoyed this faith. Every visit I was very relieved disease. Tel: 0839820792.

• I was patient, had to clinics of Dr. Le Duc Tin. I see very conscientious doctor patient care, answer any questions and very dedicated staff from the receptionist to the children tested, nursing. Clinics very clean and spacious. I'm very satisfied. Tel: +841227880829.

Search

News

Customer support